IL17A and arthritic joint disease: In fact, anti-IL-17A and anti-IL-17 receptor A aptamers inhibited the progression of experimental autoimmune encephalomyelitis (EAE), glucose-6-phosphate isomerase (GPI)-induced arthritis, collagen-induced arthritis, and osteoarthritis in mice [17,27,28].